RxDoctor Payments Data

Brad Webb

Foot & Ankle Surgery · Cedar City, UTNPI 1518900562

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,452 of the $3,545 with a category attached, or 69.2%. Stryker accounts for 88.6% of it on its own, with 14 other manufacturers making up the rest. That places this record below the midpoint for foot & ankle surgery clinicians in UT, where the typical reported total is $3,480.

$3,545in general payments, 2019–2025

Across 47 payments — averaging $75.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Smith+Nephew$131
  • Abbott$55
  • Paragon 28, Inc.$36
  • Solventum Corporation$26
  • Misonix Inc$24
  • plus $133 from 9 others

What the payments were for

  • Travel & lodging$2,45269%
  • Food & beverage$1,09431%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,545 in reported general payments places this provider in the 50th percentile of 104 foot & ankle surgery providers in Utah.

See all foot & ankle surgery providers in Utah

Medicare billing

Part B allowed, 2024
$217,692
Medicare patients
419
Services billed
3,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin12$13,617
ErtapenemErtapenem Sodium22$8,348
Linezolid26$5,679
SantylCollagenase Clostridium Hist.16$4,847
Cephalexin101$999
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$609
Gabapentin68$579
Terbinafine Hcl17$441
Cefazolin Sodium17$388
Mupirocin16$359
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$327
Diclofenac Sodium13$304
Doxycycline Monohydrate25$272
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim42$270
Silver Sulfadiazine26$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$131$4,84716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 104 foot & ankle surgery providers in Utah.

Other foot & ankle surgery in Cedar City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →